Know the Other "Omics": Exploring Drug and Diagnostics Development Through Proteomics

Table of Contents

Executive Summary

• Strategic Considerations
• Stakeholder Implications
• Introduction
• Inherent Challenges in Researching Proteins
• Proving the Value of Proteomics
• Understanding the Proteomics Approach
  • Sample Preparation
  • Separation and Capture, Analysis and Identifi cation
  • Planning Ahead for Clinical Validation
• Recent Perspectives on Proteomic Technologies
  • Two-Dimensional Gel Electrophoresis
  • Mass Spectrometry
  • Bioinformatics Tools
• Biopharma Players in the Protein Research Arena
  • Caprion Proteomics
  • NextGen Sciences
  • Power3 Medical Products
• Notable Initiatives in Proteomics
  • Clinical Proteomic Technologies for Cancer
    • Spectrum Expert Commentary
• Revitalizing Personalized Medicine Through Proteomics
  • Improvements in Proteomics
    • Protein Assay Platforms
    • Spectrum Expert Commentary (cont.)
    • Assay Availability
  • At a Major Turning Point
  • About the Author
  • Human Plasma Proteome Project
• Outlook
  • Overcoming Key Challenges
  • Building Capacity Through Collaboration

Tables

• 1. Select Diagnostic Tests Based on Protein Biomarkers
• 2. Advantages and Disadvantages of 2DGE and MS Technologies
• 3. Select Protein Sequencing Databases
• 4. Select Proteomics Companies of Interest
• 5. Participants in the Clinical Proteomic Technologies for Cancer Initiative
• 6. Pharmaceutical and Diagnostics Company Sponsors of the Human Plasma Proteome Project

Figures

• 1. FDA Approval of NMEs Compared with R&D Spending, 2000-2008
• 2. Sensitivities and Specifi cities of Select FDA-Approved Protein Biomarkers
• 3. Proteomics Research Process
• 4. Comparison of Protein Sample Sources
• 5. Number of Alliances Involving Proteomics, 2001-2008

Expert Commentary

• Revitalizing Personalized Medicine Through Proteomics
• M. Walid Qoronfl eh, Ph.D., M.B.A.,
• Vice President of Business Development at NextGen Sciences